Characterization of the Pharmacokinetic and Pharmacodynamic Profile of Apraglutide, a Glucagon-Like Peptide-2 Analog, in Healthy Volunteers

Data Supplement

• Supplemental Data -

  Appendix 1. Pharmacokinetic/Pharmacodynamic Model Description.
  

  Table S1. Baseline Characteristics of Subjects in the Present Study (TA799-002) by Treatment Arm.
  

  Table S2. Treatment-Emergent Adverse Events.
  

  Table S3. Predicted Plasma Apraglutide and Citrulline Levels per Kilogram Body Weight.
  

  Figure S1. Subject disposition.
  

  Figure S2. Population pharmacokinetic/pharmacodynamic model structure and parameter definitions.
  

  Figure S3. Observed versus population and individual predicted apraglutide plasma concentrations on linear (top) and log10 scales, and plasma citrulline.